DETAILED NOTES ON LINSITINIB STRUCTURE

Thyroid eye disease (TED) therapy Tepezza – the highest asset in Amgen's $26 billion takeover of Horizon in 2023 – could be dealing with competition from an easier-to-dose alternate from Sling Therapeutics.The inflammation can drive the eyes forward or result in the eyes and eyelids to become crimson and swollen. Since the disease progresses it